BlackRock’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

BlackRock’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51,334	Closed	-$164K	–	6083
2022 Q1	$164K	Sell	51,334 -1,035	-2%	-$2.98K	﹤0.01%	5160
2021 Q4	$151K	Buy	52,369 +575	+1%	+$2.14K	﹤0.01%	5167
2021 Q3	$205K	Buy	51,794 +28,944	+127%	+$149K	﹤0.01%	4986
2021 Q2	$137K	Sell	22,850 -345,376	-94%	-$2.44M	﹤0.01%	4976
2021 Q1	$4.47M	Buy	368,226 +122,227	+50%	+$1.74M	﹤0.01%	3991
2020 Q4	$3.59M	Sell	245,999 -1,922	-0.8%	-$24.5K	﹤0.01%	3830
2020 Q3	$2.85M	Buy	+247,921	New	+$3.18M	﹤0.01%	3797

BlackRock's CMPI Position: Q2 2022 in Review

BlackRock sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 51,334 shares — an estimated $164K sold.

BlackRock first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $4.47M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

BlackRock reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
BlackRock sold 51,334 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $164K.
BlackRock first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
BlackRock's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $4.47M in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.